Odyssey Therapeutics, Inc. (ODTX) Stock Score, Valuation & Financial Research

Odyssey Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ODTX

Odyssey Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 18.48. These figures are a research snapshot, not a buy or sell recommendation.

What Odyssey Therapeutics, Inc. does

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Odyssey Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future collaborations to fund the research, development, and clinical testing of small molecule and protein therapeutic candidates for autoimmune and inflammatory diseases.

Products and services

  • The company is developing a pipeline of clinical-stage product candidates, including its lead program OD-001, a RIPK2 inhibitor targeting autoimmune and inflammatory conditions.

Customer types

Patients with autoimmune and inflammatory diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, data collection, and the manufacturing of drug substances and products for clinical use. Specific supplier names are unnamed. Source

Business strengths to evaluate

  • Deep knowledge of human immune biology Source
  • Expertise in both small molecules and protein therapeutics Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party clinical trial sites and manufacturing partners Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ODTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 18.48
Market capitalization:
887.81M (currency not supplied)
Revenue:
USD 2.98M
Net income:
USD -148.65M
Free cash flow:
USD -130.7M
Cash:
USD 82.03M
Total debt:
USD 24.83M
EPS:
USD -5.39

What stands out

  • Free cash flow is USD -130.7M, negative for the stored period.
  • The balance sheet shows USD 82.03M of cash versus USD 24.83M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a severe debt stress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4391.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -4994.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 57.21M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ODTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ODTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ODTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ODTX to reach sustainable profitability?
  • What does the current severe debt stress warning mean for the reliability or interpretation of ODTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research ODTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.